Table 2 “Gastro-intestinal” adverse events reported in clinical trials comparing tirzepatide (5, 10, and 15 mg pre week) with selective GLP-1 receptor agonists (dulaglutide 1.5 mg/week and semaglutide 1.0 mg per week)
Study | Phase 2 (GPGB), 26 weeks [14] | SURPASS-2, 40 weeks [16] | ||||||
|---|---|---|---|---|---|---|---|---|
Agent | Tirzepatide | Dulaglutide | Tirzepatide | Semaglutide | ||||
Dose | 5 mg | 10 mg | 15 mg | 1.5 mg | 5 mg | 10 mg | 15 mg | 1 mg |
Patient numbers per arm | 55 | 51 | 53 | 54 | 470 | 469 | 470 | 469 |
Effectiveness | ||||||||
HbA1c reduction vs. baseline [%]* | −1.6 | −2.0 | −2.4 | −1.1 | −2.0 | −2.2 | −2.3 | −1.9 |
Body weight reduction vs. baseline [kg]† | −4.8 | −8.7 | −11.3 | −2.7 | −7.8 | −10.3 | −12.4 | −7.8 |
Adverse events | ||||||||
Nausea | 20.0 | 21.6 | 39.6 | 29.6 | 17.4 | 19.2 | 22.1 | 17.9 |
Vomiting | 7.3 | 15.7 | 26.4 | 9.3 | 5.7 | 8.5 | 9.8 | 8.3 |
Diarrhoea | 23.6 | 23.5 | 32.1 | 16.7 | 13.2 | 16.4 | 13.8 | 11.5 |
Constipation | 3.6 | 11.8 | 3.8 | 5.6 | 6.8 | 4.5 | 4.5 | 5.8 |
Any “gastro-intestinal” adverse event | 32.7 | 51.0 | 66.0 | 42.6 | 40.0 | 46.1 | 44.9 | 41.2 |
Adverse event leading to treatment discontinuation | 9.1 | 5.9 | 24.5 | 11.1 | 6.0 | 8.5 | 8.5 | 4.1 |